Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
| Autor: | Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz, Miguel Ángel Rubio-Herrera |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Gorgojo-Martínez JJ] Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, Madrid, Spain. [Mezquita-Raya P, de Torres-Sánchez A] Department of Endocrinology and Nutrition, Hospital Universitario Torrecárdenas, Almería, Spain. [Carretero-Gómez J] Department of Internal Medicine, University Hospital of Badajoz, Badajoz, Spain. [Castro A] Department of Cardiology, University Hospital la Paz, IdiPAZ, Biomedical Research Center-Cardiovascular Diseases (CIBERCV-ISCIII), Madrid, Spain. [Cebrián-Cuenca A] Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), Cartagena, Spain. [Soler MJ] Grup de Recerca de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II [ENFERMEDADES]
enfermedades del sistema digestivo::enfermedades gastrointestinales [ENFERMEDADES] acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::hipoglicemiantes [COMPUESTOS QUÍMICOS Y DROGAS] Aparell digestiu - Malalties Other subheadings::Other subheadings::/adverse effects [Other subheadings] General Medicine Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [DISEASES] Digestive System Diseases::Gastrointestinal Diseases [DISEASES] Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] Antidiabètics - Ús terapèutic Diabetis no-insulinodependent Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [CHEMICALS AND DRUGS] |
| Zdroj: | Scientia |
| Popis: | Gastrointestinal adverse events; Obesity; Type 2 diabetes Esdeveniments adversos gastrointestinals; Obesitat; Diabetis tipus 2 Eventos adversos gastrointestinales; Obesidad; Diabetes tipo 2 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss. This work has been funded by Novo-Nordisk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|